Coave Therapeutics
PrivateLast Round
Series A
Jan 9, 2025
Total Funding Raised
$100.8M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Coave Therapeutics operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Series A round in January 2025.
Coave Therapeutics is a biotechnology company that develops targeted gene therapies for rare ocular and central nervous system (CNS) diseases using its proprietary ALIGATER™ platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Coave Therapeutics Comparables
Compare Coave Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SparingVision | 87% | |
| Capsida Biotherapeutics | 84% | |
| Latus Bio | 83% |
For institutional investors. Book with your work email.
Coave Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 9, 2025 | ||||
| Strategic | Sep 16, 2021 | ||||
| Series B | Jul 21, 2021 | ||||
| Series B | Nov 8, 2017 | ||||
| Series A | Jul 8, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Coave Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fund+ | Series B, Series A |
| Seroba Life Sciences | Series A, Series B |
| Pontifax Venture Capital | Series B |
| Turenne Groupe | Series B, Series A |
| UI Investissement | Series A |
| Eurazeo Investment Manager | Series B |
| V-Bio Ventures | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 20, 2026
Open roles increased to 7, 2.6x the trailing average.
- Nov 19, 2025
Unveiled lead SCS gene therapy for retinal vascular diseases.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 5, 2026
Coave Therapeutics SA will present new preclinical data on its CoTx-101 retinal gene therapy program, including non-human primate findings, at the 26th Euretina Congress in Austria from Oct 1st–4th '26.
- attends_eventSep 24, 2026
Coave Therapeutics SA's CEO, Rodolphe Clerval, gives an oral corporate presentation at the Euretina Innovation Spotlight (EIS) conference in Austria on Sep 30th '26.
- hiresSep 16, 2026
Nora Dimon joins Coave Therapeutics SA as Vice President of Clinical Development, bringing more than two decades of leadership in ophthalmology and retinal diseases across clinical development, medical affairs, and regulatory strategy.
For institutional investors. Book with your work email.
Coave Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Coave Therapeutics's valuation, stock price, and market status.
Is Coave Therapeutics a public or private company?
Coave Therapeutics is a private company.
What is the current stock price of Coave Therapeutics?
Coave Therapeutics is a private company, so its shares have no public market price. Caplight tracks Coave Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Coave Therapeutics worth (valuation)?
Valuation information for Coave Therapeutics is not publicly available.
Can I buy Coave Therapeutics stock?
Coave Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Coave Therapeutics's last funding round?
Coave Therapeutics's most recent funding round was Series A on January 9, 2025.
Who are the main investors in Coave Therapeutics?
Key investors in Coave Therapeutics include Seroba Life Sciences, Novo Holdings, Bpifrance, Kurma Partners.
Will Coave Therapeutics IPO soon?
No public IPO plans have been announced for Coave Therapeutics.
How can I track Coave Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Coave Therapeutics's shares on secondary markets.